Skip to main content

Table 2 Parameter used in the base-case

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Type of parameter

Base Case value

References

Demographics

Population

60,795,612

[18]

Male in the health plan (% of total)

48.5%

[17]

Paediatric in the health plan (% of total)

11.9%

[17]

Annual population growth

0.5%

[18]

Paediatric weight (Kg)

18.5

[21]

Adult weight (Kg)

70.6

[22]

Epidemiology

HA prevalence in male

12.7 per 100,000

[16]

Severity distribution of the disease

 Mild

39.7%

[16]

 Moderate

14.1%

 Severe

46.2%

Patients without inhibitors

 Mild

99.1%

[16]

 Moderate

96.3%

 Severe

81.6%

Treatment regimen among adults

 On demand

42.8%

[16]

 Prophylaxis

55.2%

Treatment regimen among paediatrics

 On demand

0%

Assumption based on the opinion of clinical experts

 Prophylaxis

100%

Costs

rFVIIIFc unit cost (€/IU)

0.72

[25]

Advate® unit cost (€/IU)

0.65

[25]

Kogenate® unit cost (€/IU)

0.69

[25]

Refacto® unit cost (€/IU)

0.69

[25]

Helixate® unit cost (€/IU)

0.69

[25]

Recombinate® unit cost (€/IU)

0.60

[25]

Plasma-derived unit cost (€/IU)

0.60

[25]